Traditional Chinese medicine composition for treating adenoid hypertrophy as well as preparation method and application thereof

Abstract

The invention belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition for treating adenoid hypertrophy as well as a preparation method and application of the traditional Chinese medicine composition. 13-17 parts of astragalus membranaceus, 8-12 parts of codonopsis pilosula, 5-7 parts of bighead atractylodes rhizome, 5-7 parts of pericarpium citri reticulatae, 5-7 parts of poria cocos, 2-4 parts of rhizoma pinellinae praeparata, 5-7 parts of honey-fried licorice root, 5-7 parts of thunberg fritillary bulb, 2-4 parts of biond magnolia flower, 5-7 parts of mint, 5-7 parts of platycodon grandiflorum, 8-12 parts of Chinese yam and 5-7 parts of lotus seed pulp. The traditional Chinese medicine composition effectively improves the effect of treating adenoid hypertrophy.

Description

Technical Field

[0001] The present invention belongs to the technical field of traditional Chinese medicine compositions, and in particular relates to a traditional Chinese medicine composition for treating adenoids hypertrophy, a preparation method and an application thereof. Background Art

[0002] Adenoid hypertrophy is a condition characterized by a pathological enlargement of the adenoids, lymphoid tissue located in the center of the nasopharynx, beyond their normal physiological size. This condition can lead to nasopharyngeal stenosis, which can cause respiratory distress and decreased cardiopulmonary function. Persistent airway obstruction can lead to mouth breathing, resulting in abnormal facial development and the so-called "adenoid facies." Patients often experience complications such as sinusitis, otitis media, and sleep apnea.

[0003] Glucocorticoid nasal sprays and surgical removal are the main treatments for this disease. Although glucocorticoids can reduce inflammation and relieve swelling, they have poor long-term efficacy and are prone to recurrence. While surgery can completely remove the adenoids, it carries risks. Studies have also shown that children who undergo adenoidectomy (or combined with tonsillectomy) are at increased risk of developing asthma later in life, leading to low parental acceptance.

[0004] Studies have shown that although 45% of children with AH experienced significant improvement in symptoms immediately after treatment, 70% of these children still underwent adenoidectomy during the two-year follow-up period, suggesting that the long-term efficacy of drug therapy is suboptimal. Currently, adenoidectomy is the main surgical treatment for pediatric AH. While this procedure completely removes the adenoids, it carries certain risks and adverse effects: delayed intraoperative and postoperative bleeding is the most common risk of adenoidectomy, with studies showing that the incidence of intraoperative bleeding in traditional adenoidectomy is as high as 14%. Studies have also shown that early anesthesia exposure affects the development of a child's nervous system, with behavioral abnormalities in children after anesthesia becoming increasingly common. Furthermore, adenoid removal may affect a child's immune system, and children who undergo adenoidectomy (or combined tonsillectomy) are at higher risk of developing asthma later in life. Summary of the Invention

[0005] The technical problem to be solved by the present invention is to provide a traditional Chinese medicine composition for treating adenoids hypertrophy, a preparation method and application thereof, so as to effectively improve the effect of treating adenoids hypertrophy.

[0006] The embodiment of the present invention discloses a traditional Chinese medicine composition for treating adenoids hypertrophy, comprising the following traditional Chinese medicine components in parts by weight: 13-17 parts of astragalus, 8-12 parts of codonopsis, 5-7 parts of atractylodes, 5-7 parts of tangerine peel, 5-7 parts of poria, 2-4 parts of pinellia, 5-7 parts of roasted liquorice, 5-7 parts of thunbergia, 2-4 parts of magnolia, 5-7 parts of mint, 5-7 parts of platycodon, 8-12 parts of yam, and 5-7 parts of lotus seed meat.

[0007] Preferably, the Chinese medicinal components include the following parts by weight: 15 parts of Astragalus, 10 parts of Codonopsis, 6 parts of Atractylodes, 6 parts of Tangerine Peel, 6 parts of Poria, 3 parts of Pinellia, 6 parts of Radix Glycyrrhizae, 6 parts of Fritillariae Thunbergii, 3 parts of Magnolia, 6 parts of Menthol, 6 parts of Platycodon, 10 parts of Chinese Yam, and 6 parts of Lotus Seed Meat.

[0008] The present invention discloses a method for preparing the Chinese medicine composition, comprising the following steps: Soak mint and French pinellia separately; mix other Chinese medicinal components and soak them; After the soaked French Pinellia is added to water and boiled for a period of time, other Chinese medicinal components except mint are added, and after boiling for a period of time, mint is added and boiled to obtain medicinal residues and medicinal liquid; Add 6-8 times the amount of water to the dregs and boil to obtain the medicinal solution; The medicinal liquids obtained from the two decoctions are combined, allowed to settle, filtered, and concentrated to obtain a traditional Chinese medicine composition.

[0009] Preferably, after concentration, a clear paste is obtained, and the clear paste is mixed with maltose to obtain a traditional Chinese medicine composition.

[0010] Preferably, the soaked Pinellia ternata is decocted in water for 30 minutes, and then other Chinese medicinal components except mint are added and decocted for 1.3-1.5 hours. Mint is added and decocted for 10 minutes to obtain medicinal residues and medicinal liquid.

[0011] Preferably, the concentration is to a relative density of 1.12-1.25.

[0012] Preferably, the ratio of the weight of maltose to the total weight of the Chinese medicinal components is 1-2:13-15.

[0013] The embodiment of the present invention discloses an application of the traditional Chinese medicine composition, which is used to prepare a medicine for treating adenoid hypertrophy.

[0014] Preferably, the adenoids hypertrophy is pediatric adenoids hypertrophy.

[0015] The present invention has the beneficial effects of selecting 13-17 parts of Astragalus, 8-12 parts of Codonopsis, 5-7 parts of Atractylodes, 5-7 parts of Tangerine Peel, 5-7 parts of Poria, 2-4 parts of Pinellia, 5-7 parts of Radix Glycyrrhizae Preparata, 5-7 parts of Fritillariae Thunbergii, 2-4 parts of Flos Magnoliae, 5-7 parts of Mentha, 5-7 parts of Platycodon, 8-12 parts of Chinese Yam, and 5-7 parts of Lotus Seed Meat as important components, and in terms of preparation, controlling the soaking and decocting timing of Mentha and Pinellia so that more effective ingredients beneficial for treating adenoid hypertrophy in children among the Chinese medicinal components can enter the product. The Chinese medicine composition obtained by adopting the formula and preparation method of the present application has better effect, more significant long-term therapeutic effect, lower recurrence rate, and more lasting effect than Western medicine and conventional Chinese medicine.

[0016] The main pathogenesis of adenoids hypertrophy in children with lung and spleen qi deficiency is spleen and lung qi deficiency, failure of clear yang to rise, and phlegm and dampness stagnation. This composition uses Astragalus and Codonopsis as the main drugs, which can nourish the lungs and strengthen the spleen, strengthen the defense and consolidate the exterior, and fundamentally reverse the qi deficiency state of the children; Atractylodes macrocephala, Chinese yam, Poria cocos, and lotus seeds that can strengthen the spleen and eliminate dampness and the Chinese pinellia ternata, dried tangerine peel, and thunbergia thunbergii that can dry dampness and resolve phlegm are the auxiliary drugs. Atractylodes macrocephala, Chinese yam, Poria cocos, and lotus seeds help the spleen and stomach to function well while helping phlegm and dampness to move downward. The combination of Chinese pinellia ternata, dried tangerine peel, and thunbergia thunbergii can soften and disperse nodules. Damp phlegm accumulation is the symptom of adenoids hyperplasia. The auxiliary drugs assist the main drugs, eliminate phlegm and disperse nodules, and take both the symptoms and the root cause into consideration; Magnolia officinalis is pungent and warm to open the nose, Platycodon grandiflorum is the boat, and mint is pungent and cool to dispel wind. The three guide the drugs directly to the diseased area and restrain the warm and dryness of the main and auxiliary drugs, and all serve as adjuvant drugs; and roasted licorice is the guiding drug to harmonize the drugs, invigorate qi and harmonize the middle, and alleviate the harshness of the drugs. DETAILED DESCRIPTION

[0017] Example 1 A traditional Chinese medicine composition for treating adenoids hypertrophy comprises the following traditional Chinese medicine components in parts by weight: 15 parts of astragalus, 10 parts of codonopsis, 6 parts of atractylodes, 6 parts of tangerine peel, 6 parts of poria, 3 parts of pinellia, 6 parts of roasted liquorice, 6 parts of thunbergia bulb, 3 parts of magnolia, 6 parts of mint, 6 parts of platycodon, 10 parts of yam, and 6 parts of lotus seed meat.

[0018] The preparation is carried out in accordance with the "Specifications for Clinical Application and Preparation Technology of Traditional Chinese Medicine Paste Prescriptions" (DB32 / T 4870-2024). The specific method is as follows: 1. Refining malt sugar Place 10 parts of malt sugar in a stainless steel pot and add an equal amount of drinking water.

[0019] Bring the mixture to a gentle boil for 1-2 hours, stirring continuously, until it is golden in color and forms beads of water.

[0020] Filter through No. 5 sieve (120 mesh) to remove impurities and keep warm for later use.

[0021] 2. Preparation of medicinal pieces Except for mint and Pinellia ternata, the other medicinal pieces are placed in a clean decoction container, added with 8 to 10 times (the weight of the medicinal material) drinking water, and soaked at room temperature for 1 to 2 hours, until there is no white core when the piece is broken.

[0022] Soak a single bag of French Pinellia.

[0023] Add the mint in a single bag and shorten the soaking time to 30 minutes.

[0024] 3. Decoction First decoction: After boiling over high heat, add in the Pinellia ternata and simmer for 30 minutes; add in other herbs and keep boiling for 1.5 hours; add the mint bag 10 minutes before the end of the decoction.

[0025] Second decoction: Add 6-8 times the amount of water to the medicinal residue, boil over high heat, then simmer for 1 hour.

[0026] The two decoctions were combined, allowed to settle for 4 h, and filtered through 120 mesh to obtain about 600 parts of the total filtrate.

[0027] 4. Concentration The filtrate is placed in a vacuum concentration tank (or an open copper pot), first over high heat and then over low heat, stirring continuously, and concentrated to a relative density of 1.12-1.25 (measured at 80°C), to obtain about 90 parts of clear paste.

[0028] 5. Collect the cream Continue to heat the paste over low heat, slowly add the refined malt sugar, and continue stirring.

[0029] Control the end point: Use a bamboo stick to lift the paste to form a "hanging flag" or drip water into beads, or draw it into a thread without sticking to your hands.

[0030] 6. Quality Inspection and Storage Appearance inspection: The paste is black, smooth and shiny, without burnt odor, rancidity, sandiness or foreign matter.

[0031] The relative density is 1.25-1.35 (25°C), and the insoluble matter meets the requirements of the pharmacopoeia.

[0032] The label should clearly indicate the ingredients, usage, contraindications, and storage conditions; store in a cool, dry place or refrigerate at 2-10°C to prevent moisture and mildew.

[0033] Example 2 1. Total Prescription Volume A traditional Chinese medicine composition for treating adenoids hypertrophy comprises the following traditional Chinese medicine components in parts by weight: 225g of astragalus, 150g of codonopsis, 90g of atractylodes, 90g of tangerine peel, 90g of poria, 45g of pinellia, 90g of roasted liquorice, 90g of thunbergia, 45g of magnolia, 90g of mint, 90g of platycodon, 150g of yam, and 90g of lotus seed meat (30-day supply); the total amount of the decoction pieces is 1335g.

[0034] Malt sugar: 150g.

[0035] 2. Pre-treatment of medicinal pieces Acceptance of medicinal pieces: in accordance with the 2020 edition of the Pharmacopoeia of the People's Republic of China, with impurities removed.

[0036] Special treatment: Boil the Pinellia ternata for 30 minutes first; add the mint later.

[0037] 3. Maltose Refining Add 150 g malt sugar to 150 mL of an equal amount of drinking water, keep it slightly boiling and stir continuously for about 1 hour, until it forms beads and is crispy but not sticky to teeth. Pass through a No. 5 sieve and keep warm at 60-70℃ for later use.

[0038] 4. Soak Except for mint and Pinellia ternata, the remaining pieces of medicine are placed in a clean stainless steel pot, added with 8 times the amount of drinking water (10.8L), and soaked at room temperature for 2 hours.

[0039] Soak a single bag of French Pinellia.

[0040] Wrap the mint separately and soak it for 30 minutes.

[0041] 5. Decoction First decoction: After boiling over high heat, add in the Pinellia ternata and simmer for 30 minutes; add in other herbs and keep boiling for 1.5 hours; add the mint bag 10 minutes before the end of the decoction.

[0042] Second decoction: Add 6 times the amount of water (7.2L) to the medicinal residue and simmer for 1 hour.

[0043] Combine the three solutions, let them settle for 4 hours, filter through 120 mesh, and obtain 8 L of filtrate.

[0044] 6. Concentration The filtrate was placed in a vacuum concentration tank (or stainless steel open pot), first boiled over high heat and then over low heat, kept at a slight boil and stirred continuously, and concentrated to a relative density of 1.20 (measured at 80°C) to obtain 1200 mL of clear paste.

[0045] 7. Collect the cream Continue to simmer the clear paste and slowly add the malt sugar that has been refined in advance.

[0046] Continue stirring and control the end point: use a bamboo stick to lift the paste into a "hanging flag" shape, and you will get about 1200ml of sugar paste.

[0047] 8. Packaging and Cooling Cream Pack while hot: clean and dry glass wide-mouth bottles, each bottle is about 400ml (10-day supply), a total of 3 bottles.

[0048] Cooling cream: Cover the bottle mouth with sterilized gauze, place it in a clean cooling cream room and let it cool down to room temperature naturally, then close the inner and outer lids tightly.

[0049] 9. Quality Inspection Appearance: black, shiny, fine, no particles, no burnt spots, no sanding, no rancid smell; Relative density: about 1.35.

[0050] Insoluble matter: Take 20g and dissolve it in hot water for 3 minutes, and no obvious charred debris will be found.

[0051] 10. Labeling and Storage Label: product name, ingredients, net content per bottle, directions for use, contraindications, batch number, production date.

[0052] Storage: Store in a cool, dry place; refrigerate at 2-10°C in summer.

[0053] 11. Usage and Dosage (30-day plan) Take 20 ml (about one tablespoon) twice a day with warm water; avoid raw or cold food, radish, strong tea, spicy or greasy food.

[0054] At this point, the 30-day dose of maltose paste formula is prepared and can be taken by one person for 30 consecutive days.

[0055] Comparative Example 1 A traditional Chinese medicine composition for treating adenoids hypertrophy is composed of the following components in parts by weight: 120g of Atractylodes macrocephala, 120g of Poria cocos, 60g of Scutellaria baicalensis, 90g of Fritillaria thunbergii, 45g of Magnolia florid, 90g of Mentha, 120g of Platycodon grandiflorum, 60g of Forsythia suspensa, 150g of Scrophularia ningpoensis, 60g of Red Peony Root, 60g of Taraxacum mongolicum, 90g of Acorus calamus, 90g of raw oyster, and 180g of scorched Shenqu.

[0056] The paste prescription was prepared by the method of Example 2.

[0057] Example 3 90 children with adenoids hypertrophy of lung and spleen qi deficiency type were divided into experimental group, control group and comparative group 1, with 30 cases in each group.

[0058] In the control group, there were 16 male and 14 female children aged 2 to 7 years (mean, (4.20±1.42) years); weight ranged from 9.7 to 21.1 kg (mean, (15.62±3.48) kg); and adenoid hypertrophy grade I, II, and III were 5, 13, and 12 cases, respectively.

[0059] In the experimental group, there were 16 males and 14 females; their ages ranged from 2 to 7 years old, with an average of (4.53±1.48) years; their weight ranged from 9.5 to 24.8 kg, with an average of (16.47±3.34) kg; and the adenoid hypertrophy grades were 3, 17, and 10 in grade I, II, and III, respectively.

[0060] In comparison group 1, there were 18 male and 12 female children aged 2 to 7 years (mean, (4.43±1.55) years); weight ranged from 9.4 to 21.7 kg (mean, (15.89±3.56) kg); and adenoid hypertrophy grade I, II, and III were 4, 16, and 10 cases, respectively.

[0061] There was no significant difference in the general condition of the three groups of children (P>0.05), and they were comparable. The experimental group used this composition (i.e., the Chinese medicine composition of Example 2), the control group used glucocorticoid nasal spray, and the comparative example 1 group used the Chinese medicine composition of comparative example 1. The treatment lasted for 4 weeks, and the patient's condition was recorded before treatment, after treatment, and 30 days after treatment. The specific observation indicators are as follows: 1. Comprehensive symptom and sign score: Symptoms and signs of children were assessed before, after, and 30 days after treatment, and scores were recorded. Scoring criteria were developed based on the "Guidelines for Clinical Practice of Adenoid Hypertrophy in Children in Traditional Chinese Medicine" and the "Expert Consensus on the Diagnosis and Treatment of Sleep-Disordered Breathing Caused by Adenoid Hypertrophy in Children in Traditional Chinese Medicine." Primary symptoms included nasal congestion, snoring, and mouth breathing, with severity ranging from 0 for no symptoms, 2 for mild, 4 for moderate, and 6 for severe. Secondary symptoms included runny nose, cough / sputum, pharyngeal discomfort, adenoid facies, hearing loss, and loss of appetite, with severity ranging from 0 for no symptoms, 1 for mild, and 2 for severe. The total score for the combined symptoms and signs was 30 points.

[0062] 2. Overall Efficacy Observation: Based on the "Guiding Principles for Clinical Research of New Traditional Chinese Medicines (Trial Implementation)," treatment outcomes are systematically categorized into four levels, with a clearly progressive progression: Level I (cured), Level II (markedly effective), Level III (effective), and Level IV (ineffective). Level I requires complete resolution of primary clinical symptoms and signs, with significant improvement in secondary symptoms, and a total score improvement rate of 95% or greater. Level II requires significant relief of both primary and secondary clinical symptoms and signs, with a total score improvement between 70% and 95%. Level III indicates some improvement in both primary and secondary symptoms, with a total score improvement rate between 30% and 70%. Level IV indicates no significant improvement in clinical symptoms and signs, with a total score improvement rate below 30%. The nimodipine method was used to quantify the overall efficacy change: [(pre-treatment score - post-treatment score) ÷ pre-treatment score] × 100%.

[0063] 3. Electronic nasopharyngoscopy grading: Electronic nasopharyngoscopy was performed before and after treatment. Grading and scoring were performed according to the "Guidelines for the Diagnosis and Treatment of Obstructive Sleep Apnea in Children (2020)" and "Otorhinolaryngology-Head and Neck Surgery": 0% to 25% obstruction of the posterior nasal cavity was grade I, 26% to 50% was grade II, 51% to 75% was grade III, and 76% or more was grade IV.

[0064] 4. OSA-18 Quality of Life Score: The OSA-18 Quality of Life Score was used to assess children's quality of life, as described in the "Guidelines for the Diagnosis and Treatment of Obstructive Sleep Apnea in Children (2020)." This scale systematically quantifies children's quality of life before, after, and 30 days after the intervention. Scores are recorded to provide evidence for the effectiveness of each intervention. The scale consists of five sections, containing 18 questions: sleep disturbance (4 questions, scored 4-28 points), overall physical condition (4 questions, scored 4-28 points), emotional state (3 questions, scored 3-21 points), daytime functioning (3 questions, scored 3-21 points), and impact on caregivers (4 questions, scored 4-28 points). Each question is scored from 1 to 7 points based on severity, with a total score ranging from 18 to 126 points. The greater the impact on quality of life, the higher the score.

[0065] The results show: 1. Comprehensive Symptom and Sign Score: Intra-group comparisons showed that the comprehensive symptom and sign scores in both groups decreased significantly after treatment and 30 days after treatment compared to before treatment (P < 0.05). Inter-group comparisons showed that the scores in the experimental group remained significantly lower than those in the control group 30 days after treatment (P < 0.05). See Table 1 for details.

[0066] Table 1 Comparison of symptom and sign scores of each group before treatment, after treatment and 30 days after treatment ( )

[0067] Note: *P<0.05 compared with before treatment; # Compared with the control group, P<0.05.

[0068] 2. Overall Efficacy Observation: After treatment, the total effective rate was 63.3% in the control group and 80.0% in the experimental group, a statistically significant difference (P < 0.05). Thirty days after the end of treatment, the total effective rate was 33.3% in the Western medicine control group and 66.7% in the massage group, a statistically significant difference (P < 0.05). See Tables 2 and 3 for details.

[0069] Table 2 Comparison of overall efficacy after treatment n (%)

[0070] Table 3 Comparison of overall efficacy 30 days after treatment n (%)

[0071] 3. Electronic Nasopharyngoscope Grading: Before treatment, there was no statistically significant difference in the electronic nasopharyngoscope grading structure among the three groups. After treatment, the grading structure of the two groups was comparable. Thirty days after treatment, the grading structure of the experimental group was significantly better than that of the control group (P < 0.05). See Tables 4 and 5 for details.

[0072] Table 4 Comparison of adenoid hypertrophy grades after treatment n (%)

[0073] Table 5 Comparison of adenoid hypertrophy grades 30 days after treatment n (%)

[0074] 4. OSA-18 Quality of Life Score: Compared with pre-treatment, the scores of both groups decreased significantly after treatment (P < 0.05), with the experimental group's score lower than the control group's (P < 0.05). Thirty days after treatment, the experimental group's score was still significantly better than the control group's score before treatment, with the difference being statistically significant (P < 0.05). See Table 6 for details.

[0075] Table 6 Comparison of OSA-18 quality of life scores before treatment, after treatment, and 30 days after treatment ( )

[0076] Note: *P<0.05 compared with before treatment; # Compared with the control group, P<0.05.

[0077] The results showed that after treatment, the experimental group was equivalent to or better than the Western medicine control group in all observation indicators; in the follow-up 30 days after the end of treatment, the experimental group was better than the Western medicine control group in all observation indicators, indicating that this paste prescription has a good effect in treating adenoids hypertrophy in children with lung and spleen qi deficiency type, which is equivalent to glucocorticoid nasal spray, and has more significant long-term efficacy, lower recurrence rate, and more lasting effect.

[0078] Compared with the Chinese medicine composition of the present application, the efficacy of the Chinese medicine composition in the comparative example 1 group was slightly lower, and the long-term efficacy was significantly different, with a lower degree of recovery and a higher relapse rate. See Tables 7-12 for details.

[0079] Table 7 Comparison of symptom and sign scores before treatment, after treatment, and 30 days after treatment ( )

[0080] Note: *P<0.05 compared with the control group.

[0081] Table 8 Comparison of overall efficacy after treatment n( % )

[0082] Table 9 Comparison of overall efficacy observation 30 days after treatment n ( % )

[0083] Table 10 Comparison of adenoid hypertrophy grading after treatment n ( % )

[0084] Table 11 Comparison of adenoid hypertrophy grading 30 days after treatment n ( % )

[0085] Table 12 Comparison of OSA-18 quality of life scores before treatment, after treatment, and 30 days after treatment )

[0086] Note: *P<0.05 compared with the control group.

[0087] The results show that the experimental group is better than the control group 1 in all observation indicators after treatment; it is suggested that the paste has good effect in treating pediatric adenoid hypertrophy of lung and spleen qi deficiency type, and the effect is better than that of the common Chinese medicine composition for treating pediatric adenoid hypertrophy of lung and spleen qi deficiency type.

[0088] Those skilled in the art will understand that the discussion of the above any embodiment is only exemplary, and is not intended to suggest that the protection scope of the present application is limited to these examples; under the idea of the present application, the above embodiments or technical features in different embodiments can also be combined, the steps can be implemented in any order, and there are many other changes of different aspects of one or more embodiments of the present application as described above. In order to be brief, they are not provided in details.

[0089] One or more embodiments of the present application are intended to cover all such alternatives, modifications and variations falling within the broad scope of the present application. Therefore, any omission, modification, equivalent replacement, improvement, etc. made within the spirit and principles of one or more embodiments of the present application should be included in the protection scope of the present application.

Claims

1. A Chinese medicine composition for treating adenoid hypertrophy, characterized in that: The invention comprises the following traditional Chinese medicine components in parts by weight: 13-17 parts of astragalus, 8-12 parts of codonopsis, 5-7 parts of atractylodes, 5-7 parts of tangerine peel, 5-7 parts of poria, 2-4 parts of pinellia, 5-7 parts of roasted licorice, 5-7 parts of thunbergia, 2-4 parts of magnolia, 5-7 parts of mint, 5-7 parts of platycodon, 8-12 parts of yam and 5-7 parts of lotus seed meat.

2. The Chinese medicine composition according to claim 1, wherein The invention comprises the following Chinese medicinal components in parts by weight: 15 parts of astragalus, 10 parts of codonopsis, 6 parts of atractylodes, 6 parts of tangerine peel, 6 parts of poria, 3 parts of pinellia, 6 parts of roasted licorice, 6 parts of thunbergia, 3 parts of magnolia, 6 parts of mint, 6 parts of platycodon, 10 parts of yam and 6 parts of lotus seed meat.

3. A method for preparing the Chinese medicine composition according to claim 1 or 2, characterized in that: The steps include: Soak mint and French pinellia separately; mix other Chinese medicinal components and soak them; After the soaked French Pinellia is added to water and boiled for a period of time, other Chinese medicinal components except mint are added, and after boiling for a period of time, mint is added and boiled to obtain medicinal residues and medicinal liquid; Add 6-8 times the amount of water to the dregs and boil to obtain the medicinal solution; The medicinal liquids obtained from the two decoctions are combined, allowed to settle, filtered, and concentrated to obtain a traditional Chinese medicine composition.

4. The preparation method according to claim 3, wherein: After concentration, a clear paste is obtained, and the clear paste is mixed with malt sugar to obtain a traditional Chinese medicine composition.

5. The preparation method according to claim 3, wherein: The soaked French Pinellia is decocted in water for 30 minutes, and then other Chinese medicinal components except mint are added and decocted for 1.3-1.5 hours. Mint is added and decocted for 10 minutes to obtain medicinal residues and medicinal liquid.

6. The preparation method according to claim 3, wherein: Concentrate to a relative density of 1.12-1.

25.

7. The preparation method according to claim 4, characterized in that: The ratio of the weight of maltose to the total weight of the traditional Chinese medicine components is 1-2:13-15.

8. A use of the Chinese medicine composition according to claim 1 or 2, characterized in that: The traditional Chinese medicine composition is used for preparing medicine for treating adenoid hypertrophy diseases.

9. The use according to claim 8, characterized in that: The adenoids hypertrophy is adenoids hypertrophy in children.

Images